Enhancement of the immune system of chemotherapy-treated cancer patients by simultaneous treatment with thymic extract, TP-1

Shoham, Jacob; Theodor, E; Brenner, H.; Goldman, Boleslav; Lusky, Ayala; Chaitchick, Sammario

doi:10.1007/bf00205622

Cited by 18 publications

(11 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At high doses, some immunomodulators were reported not to be effective on tumor growth or even to cause immunosuppression resulting in promotion of tumor growth [26]. In the present study the highest dose of 100 mg/kg did not cause immunosuppression, but its inhibition of pulmonary metastases was the same as that of a dose of 10 mg/kg.…”

Section: Discussionsupporting

confidence: 50%

“…Since then it has been tested in vitro [2] and in vivo [22,26]. This extract has been shown to have the capacity to increase the mitogen response of mouse spleen lymphoid cells, to stimulate an increase in the theta-positive cell population in mouse spleen and human cord blood, and to stimulate the ability of mouse marrow cells to induce a graft-versus-host response in x-ray-irradiated mice [11].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of a thymic factor, thymostimulin, on growth and pulmonary metastases of Lewis lung carcinoma

Yagi

Yamashita

Tsubura

1985

Cancer Immunol Immunother

View full text Add to dashboard Cite

The antitumor and antimetastatic activities of a thymic factor, thymostimulin (TP-1), with or without cyclophosphamide (CPA) were examined in C57BL/6 mice inoculated with Lewis lung carcinoma (3LL). Tumor growth was followed by determining the tumor diameter after tumor implantation. TP-1 given to mice every 2 days after tumor implantation significantly inhibited tumor growth without affecting the survival rate. For induction of spontaneous pulmonary metastases, 3LL cells were implanted into the footpads of mice, and the implanted tumor was removed on day 9. The antimetastatic effect of TP-1 on pulmonary metastases after removal of the primary tumor was evaluated by counting the number of pulmonary surface nodules. TP-1 showed antimetastatic activity depending on its time of administration and dose. Combined therapy with TP-1 plus CPA significantly prolonged the survival of mice with pulmonary metastases. The cytolytic activities of spleen cells on 3LL cells were enhanced in mice treated with TP-1 and/or CPA and the cytolytic activity of nonadherent spleen cells, the T-cell population, was enhanced. The role of cytolytic spleen cells in inhibiting and preventing metastases was discussed.

show abstract

Section: Discussionsupporting

confidence: 50%

Section: Discussionmentioning

confidence: 99%

Effect of a thymic factor, thymostimulin, on growth and pulmonary metastases of Lewis lung carcinoma

Yagi

Yamashita

Tsubura

1985

Cancer Immunol Immunother

View full text Add to dashboard Cite

show abstract

“…Peptides of the thymus regulate activity and induce differentiation of T-lymphocytes, thus may contribute to the host defense against cancer. Studies have reported that thymus extracts reduce the risk of infectious complications in patients undergoing cancer treatment and also might have beneficial effects on survival rate [3,5].…”

Section: Discussionmentioning

confidence: 99%

“…Thymus peptides have a very high potential to regulate its functional activity by stimulating the development and maturation of functional T-cells in the central medulla of thymus. The matured functional T-cells enter the circulation and provide adequate adaptive immune system response [3].…”

Section: Introductionmentioning

confidence: 99%

Management of Metastatic Colorectal Carcinoma with GcMAF Forte and Thymus Peptides: A Case Report

Klokol¹,

Teppone²

2016

J Clin Cell Immunol

View full text Add to dashboard Cite

In the recent years immunotherapy has gained important role in cancer management. Immunostimulating effects of thymus-derived peptides on carcinogenesis have been actively studied in both animals and humans. Gc protein derived macrophage-activating factor (GcMAF) was found to have potent effect on macrophage phagocytic activity. Immunostimulating effects of GcMAF and peptides of thymus can be effectively combined together and with other treatment modalities of cancer. The current case report demonstrates outcomes of combination of GcMAF Forte and HT Thymus (peptides of thymus) in the management of metastatic colorectal adenocarcinoma. This case study suggests that individually prescribed immunotherapy can be a promising alternative in management of advance forms of cancer, especially when options of treatment are limited.

show abstract

“…They found an increase in CD4 cells in peripheral blood and CD4/CD8 ratio. It is well known that Th increase is mediated by IL-2 and interferon synthesis [33,34], which is almost directly induced by thymostimulin. Our results also show that it decreases the CD8 cell subpopu lation.…”

Section: Discussionmentioning

confidence: 99%

Immunorestorative Effect of Thymostimulin on Surgery Immunodepression: Experimental Model

García-Lechuz

Navarro²,

Morandeira³

et al. 1993

Eur Surg Res

View full text Add to dashboard Cite

The purpose of the present study is to ascertain the immunorestorative effect of two different drugs on immunodepression induced by small bowel surgical resection in an experimental model. The potential immunorestorative effect has been measured by the ability of the drug to avoid the delay of skin allograft rejection induced by surgery and the inhibition of CD4/CD8 index changes induced by surgery in spleen tissue. 120 Wistar-Furth rats (age 12–16 weeks) anesthetized with a single intramuscular dose of ketamine (25 mg), diazepine (4 mg) and atropine (0.1 mg) were allotted to two main groups. One group received a skin graft (SG) from Fisher 344 rats and was treated with placebo, Inmunoferón® (AM-3 polypeptidic drug) or TP-II (thymostimulin) before the experiment (groups I, II, III) or treated with placebo, Inmunoferón or TP-1 before the experiment and underwent enterectomy and anastomosis (groups IV, V, VI). On the 2nd, 5th and 8th postoperative days, biopsies of the SG were taken and the signs of rejection were microscopically studied and evaluated by a pathologist as zero, incipient, moderate or massive. The other group was treated similarly, but the animals did not receive a SG and were splenectomized 5 days later. CD4 and CD8 lymphocyte subpopulations were identified by means of immunoperoxidase technique and monoclonal antibodies. Thymostimulin is able to stimulate the presence of SG rejection signs on the 2nd postoperative day in nonenterectomized animals and on the 8th postoperative day in enterectomized rats and is able to avoid the decrease of the CD4/CD8 index in spleen tissue after surgical immunodepression. AM-3 has less effect on the presence of SG rejection signs and CD4/CD8 index than thymostimulin.

show abstract

Enhancement of the immune system of chemotherapy-treated cancer patients by simultaneous treatment with thymic extract, TP-1

Cited by 18 publications

References 19 publications

Effect of a thymic factor, thymostimulin, on growth and pulmonary metastases of Lewis lung carcinoma

Effect of a thymic factor, thymostimulin, on growth and pulmonary metastases of Lewis lung carcinoma

Management of Metastatic Colorectal Carcinoma with GcMAF Forte and Thymus Peptides: A Case Report

Immunorestorative Effect of Thymostimulin on Surgery Immunodepression: Experimental Model

Contact Info

Product

Resources

About